Caisse DE Depot ET Placement DU Quebec Acquires 100 Shares of Zoetis Inc. (NYSE:ZTS)

Caisse DE Depot ET Placement DU Quebec raised its stake in shares of Zoetis Inc. (NYSE:ZTS) by 5.1% in the 3rd quarter, Holdings Channel reports. The firm owned 2,051 shares of the company’s stock after purchasing an additional 100 shares during the quarter. Caisse DE Depot ET Placement DU Quebec’s holdings in Zoetis were worth $401,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Darwin Wealth Management LLC acquired a new position in shares of Zoetis in the third quarter worth approximately $31,000. First Personal Financial Services bought a new position in Zoetis during the 3rd quarter worth approximately $33,000. Capital Performance Advisors LLP acquired a new position in shares of Zoetis in the 3rd quarter worth approximately $33,000. Quarry LP boosted its stake in shares of Zoetis by 273.2% in the 2nd quarter. Quarry LP now owns 209 shares of the company’s stock valued at $36,000 after purchasing an additional 153 shares during the last quarter. Finally, Fortitude Family Office LLC increased its position in shares of Zoetis by 1,387.5% during the third quarter. Fortitude Family Office LLC now owns 238 shares of the company’s stock worth $46,000 after buying an additional 222 shares during the period. 92.80% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on ZTS. BTIG Research upped their price target on shares of Zoetis from $220.00 to $225.00 and gave the company a “buy” rating in a research report on Monday, August 12th. Leerink Partnrs raised Zoetis to a “strong-buy” rating in a research note on Monday. Argus upgraded Zoetis to a “strong-buy” rating in a report on Friday, August 9th. Leerink Partners started coverage on shares of Zoetis in a research report on Monday. They issued an “outperform” rating and a $215.00 price target for the company. Finally, Piper Sandler raised their target price on Zoetis from $195.00 to $210.00 and gave the company an “overweight” rating in a report on Wednesday, August 14th. Eleven analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $220.80.

Zoetis Stock Performance

NYSE ZTS opened at $176.94 on Wednesday. The company has a market capitalization of $79.83 billion, a PE ratio of 33.26, a price-to-earnings-growth ratio of 2.71 and a beta of 0.89. The company has a debt-to-equity ratio of 1.26, a quick ratio of 2.27 and a current ratio of 3.69. Zoetis Inc. has a 52-week low of $144.80 and a 52-week high of $201.92. The company has a 50-day simple moving average of $183.16 and a 200 day simple moving average of $181.01.

Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Monday, November 4th. The company reported $1.58 EPS for the quarter, beating the consensus estimate of $1.46 by $0.12. Zoetis had a return on equity of 51.98% and a net margin of 26.55%. The business had revenue of $2.40 billion for the quarter, compared to the consensus estimate of $2.29 billion. During the same quarter in the prior year, the business earned $1.36 earnings per share. Zoetis’s revenue for the quarter was up 11.6% on a year-over-year basis. On average, research analysts predict that Zoetis Inc. will post 5.9 EPS for the current year.

Zoetis Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Tuesday, December 3rd. Stockholders of record on Thursday, October 31st were paid a dividend of $0.432 per share. The ex-dividend date of this dividend was Thursday, October 31st. This represents a $1.73 annualized dividend and a dividend yield of 0.98%. Zoetis’s payout ratio is 32.52%.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.